Melanoma vaccines

Expert Review of Vaccines

Volumn 7, Issue 7, 2008, Pages 937-949

  Riley, Lee B ^a   Agarwala, Sanjiv S ^a  

^a ST LUKE S HOSPITAL   (United States)

Author keywords

Adjuvant; Antigen; Cytokine; Dendritic cell; Melanoma; Peptide; Vaccine

Indexed keywords

ALLOVECTIN 7; ALVAC MINIMAGE 1; ALVAC MINIMAGE 3; BCG VACCINE; BETA 2 MICROGLOBULIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DETOX PC; GAMMA1B INTERFERON; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 75; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; INTERFERON; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; M VAX; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELACINE; MELAN A; MELANOMA ANTIGEN 1; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; PEPTIDE VACCINE; PERFORIN; RAG2 PROTEIN; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; AUTOIMMUNITY; CANCER REGRESSION; CELL ACTIVATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INFECTION PREVENTION; MELANOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

CANCER VACCINES; HUMANS; MELANOMA;

EID: 51349156654     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.7.937     Document Type: Review

References (92)

1. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64(3), 529-564 (1994).
2. Kessler E, Schwartz P, Antebi E. Spontaneous regression of primary malignant melanoma with metastases. Plast. Reconstr. Surg. 74(3), 427-429 (1984).
3. Satzger I, Schenck F, Kapp A, Gutzmer R. Spontaneous regression of melanoma with distant metastases - report of a patient with brain metastases. Eur. J. Dermatol. 16(4), 454-455 (2006).
4. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res. 16(3), 254-260 (2003).
5. Kim R. Cancer immunoediting: from immune surveillance to immune escape. In: Cancer Immunotherapy: Immune Suppression and Tumor Growth. Prendergast G, Jaffee E (Eds). Elsevier, NY, USA 9-25 (2007).
6. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27(2), 181-189 (2008).
7. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85-100 (1999).
8. Bodurtha AJ, Chee DO, Laucius JF, Mastrangelo MJ, Prehn RT. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res. 35(1), 189-193 (1975).
9. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001). • Important randomized trial comparing the standard high-dose IFN-α regimen to a vaccine in high-risk, surgically resected melanoma that showed the vaccine treatment was inferior.
10. Kirkwood JM, Mascari RA, Edington HD et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 88(12), 2693-2702 (2000).
11. Saleh MN, Khazaeli MB, Wheeler RH et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 52(16), 4342-4347 (1992).
12. Hanai N, Nakamura K, Shitara K. Recombinant antibodies against ganglioside expressed on tumor cells. Cancer Chemother. Pharmacol. 46(Suppl.) S13-S17 (2000).
13. King DM, Albertini MR, Schalch H et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 22(22), 4463-4473 (2004).
14. Lee FT, Rigopoulos A, Hall C et al. Specific localization, g camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res. 61(11), 4474-4482 (2001).
15. Li B, Wang H, Zhang D et al. Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. Biochem. Biophys. Res. Commun. 357(4), 951-956 (2007).
16. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006). • Excellent review of T-cell immunoregulation in melanoma.
17. Vujanovic L, Butterfield LH. Melanoma cancer vaccines and anti-tumor T cell responses. J. Cell. Biochem. 102(2), 301-310 (2007).
18. Melief CJ. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33(10), 2645-2654 (2003).
19. Schijns VE. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21(9-10), 829-831 (2003).
20. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415 (1995).
21. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68(2), 122-138 (1998).
22. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27(2), 161-167 (2008).
23. von Meyenn F, Schaefer M, Weighardt H et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology 211(6-8), 557-565 (2006).
24. Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 99, 363-407 (2008).
25. Spitler L, Grossbard M, Ernstoff M et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 18, 1614-1621 (2000).
26. Leong SP, Enders-Zohr P, Zhou YM et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J. Immunother. 22(2), 166-174 (1999).
27. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999).
28. Pasquini S, Peralta S, Missiaglia E, Carta L, Lemoine NR. Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther. 9(8), 503-510 (2002).
29. Tripathi PK, Qin H, Bhattacharya-Chatterjee M, Ceriani RL, Foon KA, Chatterjee SK. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Hybridoma 18(2), 193-202 (1999).
30. Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 20(9-10), 1466-1474 (2002).
31. Rasko J, Gough N. Granulocyte-macrophage colony stimulating factor. In: The Cytokine Handbook. Thomson A (Ed.). Academic Press, San Diego, CA, USA 343-370 (1994).
32. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993).
33. Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine 25 (Suppl. 2), B72-B88 (2007).
34. Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 110(1), 203-214 (2007).
35. Luiten RM, Kueter EW, Mooi W et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol. 23(35), 8978-8991 (2005).
36. Markovic SN, Suman VJ, Ingle JN et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am. J. Clin. Oncol. 29(4), 352-360 (2006).
37. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 155-168 (2002).
38. Del Vecchio M, Bajetta E, Canova S et al. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13(16), 4677-4685 (2007).
39. Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin. Biol. Ther. 8(3), 315-323 (2008).
40. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 25(Suppl. 2), B4-B16 (2007).
41. Ralph SJ. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines. Am. J. Clin. Dermatol. 8(3), 123-141 (2007).
42. Haigh PI, Difronzo LA, Gammon G, Morton DL. Vaccine therapy for patients with melanoma. Oncology (Williston Park) 13(11), 1561-1574 (1999).
43. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev. Vaccines 3(5), 521-527 (2004).
44. Testori A, Richards J, Whitman E et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 study group. J. Clin. Oncol. 26(6), 955-962 (2008).
45. Morton DL, Thompson JF, Kashani-Sabet M, Kelley M, Gammon G. An international, randomized, double-blind, Phase 3 study of the specific active immunotherapy agent, onamelatucel-L (CanvaxinTM), compared with placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann. Surg. Oncol. 13(Suppl. 2), 5 (2006).
46. Sosman JA, Unger JM, Liu PY et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 20(8), 2067-2075 (2002). • First article demonstrating the clinical relevance of HLA expression in terms of adjuvant therapy of melanoma with a vaccine.
47. Mitchell MS, Abrams J, Thompson JA et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon α-2b compared with high-dose interferon α-2b for resected stage III cutaneous melanoma. J. Clin. Oncol. 25(15), 2078-2085 (2007).
48. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J. Dermatol. Surg. Oncol. 19(11), 985-990 (1993).
49. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a Phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on cancer stage I-III melanoma (E1673): a trial of the Eastern oncology group. Cancer 100(8), 1692-1698 (2004). • Mature results of a large, randomized cooperative group trial of bacillus Calmette- Guérin definitely indicating the lack of benefit of this form of nonspecific immunotherapy in stage I-III melanoma.
50. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized Phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res. 13(21), 6386-6395 (2007). • Study that showed the importance and potential of multiepitope peptide vaccines. This concept is the current focus of a large cooperative group trial.
51. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3), 321-327 (1998).
52. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
53. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DCs) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17(4), 563-570 (2006). • First well-conducted, randomized trial comparing the standard chemotherapy for stage IV melanoma with vaccine therapy.
54. van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23(35), 9008-9021 (2005).
55. Connerotte T, Van Pel A, Godelaine D et al. Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 68(10), 3931-3940 (2008).
56. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12(5), 1036-1044 (1994). • First trial to stimulate major interest in the GMK vaccine that led to two large, randomized studies with this agent in the adjuvant therapy of melanoma.
57. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology 120(4), 435-446 (2007).
58. Stevenson F, Di Genova G, Cottensmeier C, Savelyeva N. Cancer vaccines. In: Cancer Immunotherapy: Immune suppression and Tumor Growth. Prendergast G, Jaffee E (Eds). Elsevier, Boston, MA, USA 183-204 (2007).
59. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol. Med. 6(6), 465-479 (2000).
60. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer Biol. 16(1), 80-88 (2006).
61. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005).
62. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195(11), 1499-1505 (2002).
63. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature 441(7090), 231-234 (2006).
64. + regulatory T cells. J. Exp. Med. 201(7), 1061-1067 (2005).
65. Allavena P, Piemonti L, Longoni D et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol. 28(1), 359-369 (1998).
66. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146(10), 3444-3451 (1991).
67. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11), 4150-4166 (1998).
68. + cells within human head and neck squamous cell carcinomas. J. Immunol. 159(2), 990-996 (1997).
69. Wagner SN, Schultewolter T, Wagner C et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab. Invest. 78(5), 541-550 (1998).
70. Morton DL. In: Society of Surgical Oncology (2006).
71. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of allovectin-7 in advanced metastatic melanoma. Melanoma Res. 16(6), 521-526 (2006).
72. Soiffer R, Hodi FS, Haluska F et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21(17), 3343-3350 (2003).
73. Hersey P, Coates AS, McCarthy WH et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol. 20(20), 4181-4190 (2002). • Large, randomized trial of adjuvant immunotherapy with a unique vaccine in resected melanoma.
74. Sondak VK, Liu PY, Tuthill RJ et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20(8), 2058-2066 (2002).
75. Mitchell MS, Harel W, Kan-Mitchell J et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann. NY Acad. Sci. 690, 153-166 (1993).
76. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21(21), 4016-4026 (2003).
77. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22(22), 4474-4485 (2004).
78. Testori A, Richards J, Whitman E et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 study group. J. Clin. Oncol. 26(6), 955-962 (2008).
79. Wolchok JD, Yuan J, Houghton AN et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol. Ther. 15(11), 2044-2050 (2007).
80. Hamid O, Solomon JC, Scotland R et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res. 13(1), 215-222 (2007).
81. Lindsey KR, Gritz L, Sherry R et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res. 12(8), 2526-2537 (2006).
82. Smith CL, Mirza F, Pasquetto V et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol. 175(12), 8431-8437 (2005).
83. Khong HT, Yang JC, Topalian SL et al. Immunization of HLA-A*0201 and/or HLA-DPβ1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27(6), 472-477 (2004).
84. Chapman PB, Wu D, Ragupathi G et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res. 10(14), 4717-4723 (2004).
85. Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A Phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22(21-22), 2904-2909 (2004).
86. Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin. Cancer Res. 10(1 Pt 1), 76-83 (2004).
87. + T-cell function in melanoma patients. J. Clin. Oncol. 21(20), 3826-3835 (2003).
88. Nicholson S, Guile K, John J et al. A randomized Phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res, 13(4), 389-393 (2003).
89. Dillman RO, Wiemann M, Nayak SK, DeLeon C, Hood K, DePriest C. Interferon-γ or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized Phase 2 trial of the cancer biotherapy research group. J. Immunother. 26(4), 367-373 (2003).
90. Rosenberg SA, Yang JC, Sherry RM et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum. Gene Ther. 14(8), 709-714 (2003).
91. + T-cell responses. J. Clin. Oncol. 21(8), 1562-1573 (2003).
92. Bettinotti MP, Panelli MC, Ruppe E et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178. Int. J. Cancer 105(2), 210-216 (2003).